https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33927 Wed 23 Jan 2019 15:30:44 AEDT ]]> NSW Cannabis Medicines Advisory Service preliminary survey results: enquirer perceptions and patient outcomes https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46742 Tue 29 Nov 2022 15:25:53 AEDT ]]> Predicting children’s social adaptation and academic achievement from father-child preschool rough-and-tumble-play and father involvement in child schooling https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53807 Tue 16 Jan 2024 14:59:33 AEDT ]]> Mepolizumab and Oral Corticosteroid Stewardship: Data from the Australian Mepolizumab Registry https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47085 Tue 13 Dec 2022 16:35:23 AEDT ]]> Cohort Profile: The Christchurch IBS cOhort to investigate Mechanisms for gut Relief and improved Transit (COMFORT) https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50052 Thu 29 Jun 2023 15:41:37 AEST ]]> Perfusion abnormalities are frequently detected by early CT perfusion and predict unfavourable outcome following severe traumatic brain injury https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34105 Thu 07 Feb 2019 14:26:15 AEDT ]]> Determinants of therapeutic lag in multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49695 Mon 29 May 2023 12:46:42 AEST ]]> Cautionary tales in the interpretation of observational studies of effects of clinical interventions https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32766 Mon 23 Jul 2018 12:49:17 AEST ]]> Mixed messages: most spinal pain and osteoarthritis observational research is unclear or misaligned https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50757 Mon 07 Aug 2023 15:11:02 AEST ]]> Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42843 n = 195; untreated n = 338). Median on-study pairwise-censored follow-up was 3.4 years (quartiles 1.2–5.5). No difference in the hazard of experiencing 3-month confirmed EDSS progression events was observed between the groups [hazard ratio (HR), 1.0; 95% confidence interval (CI), 0.6–1.7, P = 0.87]. We did not find significant differences in the hazards of confirmed EDSS improvement (HR, 1.0; 95% CI, 0.6–1.6, P = 0.91) or reaching a confirmed EDSS step ≥7 (HR, 1.1; 95% CI, 0.7–1.6, P = 0.69). Conclusion: Our pooled analysis of disease-modifying agents suggests that these therapies have no substantial effect on short- to medium-term disability outcomes in PPMS.]]> Mon 05 Sep 2022 14:44:21 AEST ]]> Best practice guidelines for the measurement of physical activity levels in stroke survivors: a secondary analysis of an observational study. https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42987 Fri 09 Sep 2022 13:56:21 AEST ]]> Contribution of different relapse phenotypes to disability in multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34630 Fri 05 Apr 2019 11:37:25 AEDT ]]>